Last reviewed · How we verify
A Study of the Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Features of Atypical/Dysplastic Nevi in Patients With Stage IIB-IIIC Melanoma
This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of atypical/dysplastic nevi (A/DN) in patients with a prior documented melanoma of Stages IIB, IIC, IIIA, IIIB, or IIIC and concurrent presence of two or more atypical nevi.
Details
| Lead sponsor | John Kirkwood |
|---|---|
| Status | RECRUITING |
| Enrolment | 30 |
| Start date | 2025-02-20 |
| Completion | 2029-05 |
Conditions
- Melanoma
Interventions
- Single agent, adjuvant anti-PD1 therapy
Primary outcomes
- Change in the aggregate pigmentation — Pre-treatment, up to 12 months
Percentage change in the total aggregate pigmentation including A/DN and benign melanocytic nevi. Percent change will be quantified from posterior trunk digital photographic images utilizing DermViz automated image comparison software.
Countries
United States